Mucositis and related gastrointestinal toxicities are also common in patients receiving EGFR inhibitors for colorectal and lung cancer: although the risk in monotherapy is low, the relative risk to develop grade ≥ 3 lesions rises significantly when EGFR inhibitors are administrated concomitantly with chemotherapy combination [50,51,52], requiring early recognition, steroids, analgesic and supportive nutritional strategies [53]. The gene discussed is EGFR; the disease is lung cancer.